Parnes, Jane R.
Amgen (United States)
3 papers on CoChat
Most cited papers
- Verified
Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
Simpson, E. L., Parnes, J. R., She, D., Crouch, S., Rees, W., Mo, M., & van der Merwe, R. (2019) · Journal of the American Academy of Dermatology
Dermatology and Skin DiseasesAsthma and respiratory diseases
Cited by 328
- Verified
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Véniant, M. M., Lu, S.-C., Atangan, L., Komorowski, R., Stanislaus, S., Cheng, Y., Wu, B., Falsey, J. R., Hager, T., Thomas, V. A., et al. (2024) · Nature Metabolism
Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity
Cited by 218
- Verified
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and MultipleAscending Dose Study of AMG 133 in Subjects with Obesity
Strande, J. L., Kurra, V., Jeswani, R., Oberoi, R., Sharpsten, L., Neutel, J., Véniant, M. M., & Parnes, J. R. (2023) · Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 7
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free